Indian hospital chains are pushing for scientific pricing models in government reimbursement schemes like the CGHS to offset rising costs. Industry leaders argue that current rates and strict procurement models limit profitability and access to advanced medical technology.
Major private hospital operators in India are intensifying their demand for a change in how the government sets reimbursement rates for patient treatments. Executives from chains like Fortis Healthcare and Apollo Hospitals, speaking at recent industry forums, argue that current government pricing models, such as the Central Government Health Scheme (CGHS), have failed to keep pace with rising operational costs and inflation.
The core of the industry's concern lies in the financial viability of treating patients under government schemes. Hospital executives state that the current fixed-rate structure does not fully account for the investment required in high-end infrastructure, qualified medical personnel, and global quality standards. When reimbursement rates remain static while input costs—such as medical supplies, electricity, and salaries—rise, the profit margin per procedure comes under significant pressure.
Beyond reimbursement rates, the industry is also challenging the common government procurement model known as L1. In this system, contracts are often awarded to the bidder offering the lowest price, regardless of the clinical superiority or long-term efficiency of the medical device. Hospital operators argue that this prioritizes immediate cost savings over the clinical outcomes that patients receive, creating a hurdle for hospitals that want to offer advanced, modern treatment options.
Another major pressure point for the sector is the widening gap in health insurance coverage. Standard insurance policies often have coverage limits around ₹5 lakh, which experts note is becoming increasingly inadequate. With the cost of advanced treatments for chronic conditions like cancer often exceeding ₹25 lakh, patients and hospitals are facing a financial mismatch. When insurance coverage falls short of the actual cost of care, hospitals may see a decline in patient volume for high-end treatments or face pressure to reduce their billing, which impacts revenue quality.
For investors in the healthcare sector, these developments are crucial for understanding future margin trends. The profitability of hospital chains is highly sensitive to their 'case mix'—or the percentage of patients they treat under insurance, government schemes, or private pay. While government-backed schemes provide high patient volumes, the pricing pressure can dampen overall profitability. The industry's push for scientific, evidence-based pricing is aimed at creating a more sustainable financial model that balances high-quality care with operational profitability. Moving forward, shareholders should monitor whether any policy reforms occur in reimbursement structures or insurance caps, as these will directly influence the financial health and expansion strategies of major hospital chains.